Sustol (granisetron ER) / Heron Therapeutics  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sustol (granisetron ER) / Heron Therapeutics
NCT00343460 / 2007-005068-29: APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Checkmark From StudyC2006
Feb 2016 - Feb 2016: From StudyC2006
Completed
3
1428
US
APF530, dexamethasone, Palonosetron Hydrochloride, placebo
Heron Therapeutics
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
09/08
02/09
NCT02106494: A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Checkmark From MAGIC trial in CINV at SABCS 2015
Dec 2015 - Dec 2015: From MAGIC trial in CINV at SABCS 2015
Checkmark From MAGIC study at ASCO breast cancer symposium
Oct 2015 - Oct 2015: From MAGIC study at ASCO breast cancer symposium
Checkmark Heron Therapeutics announced positive results from P3 MAGIC study of SUSTOL
More
Completed
3
942
US
APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
05/15
05/15

Download Options